Benefits of BV-AVD (Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) versus ABVD (doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine) in patients with advanced-stage Hodgkin's lymphoma: an analysis of the ECHELON 1 trial by the GATLA group using the Delphi Method
Titel:
Benefits of BV-AVD (Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) versus ABVD (doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine) in patients with advanced-stage Hodgkin's lymphoma: an analysis of the ECHELON 1 trial by the GATLA group using the Delphi Method
Auteur:
Pavlovsky, Astrid Altuve, Juan Ignacio Garcia Cerutti, Amalia Fiad, Lorena Kurgansky, Nicolás Warley, Fernando Negri Aranguren, Florencia
Verschenen in:
Hematology, transfusion and cell therapy
Paginering:
Jaargang 46 () nr. S6 pagina's S250-S256
Jaar:
2024
Inhoud:
Uitgever:
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular